The integrity of the vitamin D endocrine system is essential to maintain serum calcium levels within the narrow limits required to protect individuals from the adverse effects of hypercalcaemia and increased urinary calcium excretion, which increase the propensity for kidney stones, nephrocalcinosis and renal insufficiency \[[@SFV058C1], [@SFV058C2]\].

Figure [1](#SFV058F1){ref-type="fig"} summarizes the current understanding of the tight systemic and local control of vitamin D activation, inactivation and biological actions. The vitamin D hormone 1,25-dihydroxyvitamin D (1,25D) is the most potent endogenous activator of the vitamin D receptor (VDR) to exert the plethora of vitamin D biological actions, including the maintenance of mineral homeostasis and skeletal health. However, recent studies in *Cyp27b1*-null mice \[[@SFV058C3], [@SFV058C4]\], which lack the enzyme that converts 25-hydroxyvitamin D (25D) to 1,25D, and also *in vitro*, using 25D analogues chemically modified to prevent their 1-hydroxylation, have demonstrated that 25D can activate the VDR directly and can also synergize with 1,25D for VDR activation. Fig. 1.Systemic and local vitamin D bioactivation and actions. Genetic inactivation of the CYP24A1 gene (red X) compromises the tightly controlled balance between synthesis and catabolism increasing serum and intracellular 1,25D and 25D levels. These elevations cause hypercalcaemia by simultaneous exacerbation of 1,25D/VDR calcitropic actions, 25D/1,25D synergy for VDR activation and direct 25D activation of the VDR. Interventions with ketoconazole (KC) and fluconazole (FC) or phenobarbital (PB) should effectively inhibit 25D and 1,25D syntheses through a direct targeting of the key converting enzymes.

Importantly, many cells possess CYP27A1 and CYP2R1, the two main cytochrome P450s that convert vitamin D to 25D. Since this reaction is very loosely regulated, it is clear that a tight regulation of 25D conversion to 1,25D is essential to maintain serum 1,25D within the narrow limits required to avoid hypercalcaemia.

For many years, it was believed that 1,25D tightly controlled its own levels through dual mechanisms: suppressing its own synthesis and stimulating its own degradation through the induction of *CYP24A1* gene expression in most vitamin D-responsive tissues \[[@SFV058C1]\]. However, the phenotype of markedly enhanced 1,25D levels, severe hypercalcaemia and nephrocalcinosis in the *Cyp24a1*-null mice \[[@SFV058C5]\], underscored not only the importance of CYP24A1 in preventing vitamin D toxicity, but also that 1,25D suppression of its own synthesis had little, if any, pathophysiological relevance to prevent elevations in serum 1,25D above normal levels.

Recently, several loss-of-function mutations of the *CYP24A1* gene were identified \[[@SFV058C6]--[@SFV058C11]\] with a very low frequency in the general population of 0.06% for the pathogenic pE143del mutation initially described by Schlingmann \[[@SFV058C11]\]. A more recent report based on single nucleotide polymorphisms estimated, however, the frequency of predicted bi-allelic mutations of CYP24A1 in the general population to be as high as 4--20% \[[@SFV058C9]\]. Regardless of their actual frequency, these mutations were sufficient to cause infantile hypercalcaemia in children \[[@SFV058C6]--[@SFV058C11]\], followed by a long-lasting history of hypercalcaemic episodes and kidney stone formation \[[@SFV058C6]--[@SFV058C11]\], which could eventually progress to nephrocalcinosis and renal insufficiency, as described in this case report.

The absence of concurrent primary hyperparathyroidism, malignancy or a granulomatous disorder (sarcoidosis or tuberculosis) exacerbating 1,25D production and hypercalcaemia in individuals carrying the *CYP24A1* mutation has conclusively corroborated the essential role of CYP24A1 in 1,25D degradation demonstrated in the *Cyp24a1*-null mice. Furthermore, the hypercalcaemia of tuberculosis and several granulomatoses results not only from γ-interferon induction of macrophage 1,25D production but also from γ-interferon impairment of 1,25D induction of *CYP24A1* expression. Indeed, physical interactions of the DNA binding site of the VDR with Stat1, the protein that mediates γ-interferon signalling, impede 1,25D--VDR binding to the *CYP24A1* gene promoter to induce transcription \[[@SFV058C12], [@SFV058C13]\].

Not every hospital has the resources for genetic analyses to conclusively identify a *CYP24A1* mutation. However, the concurrence of persistent hypercalcaemia, hypercalciuria, suppressed parathyroid hormone (PTH), and elevated serum 1,25D levels, with normal or mildly elevated 25D in the absence of any malignancy or granulomatous disorder, should make a clinician suspicious of this rare disorder and ready to implement the best therapeutic strategy to avoid persistent hypercalcaemia and prevent disease progression to nephrocalcinosis or renal damage. Important considerations to improve current strategies are that some patients with inactivating *CYP24A1* mutations responded to ketoconazole but not to corticosteroids \[[@SFV058C6]\] and also the worsening of the hypercalcaemic episodes upon elevations in the dosage of hydrochlorothiazide \[[@SFV058C6]\].

The cytochrome P450 inhibitor ketoconazole has been used alone or in combination with corticosteroids to attenuate macrophage 1,25D production and hypercalcaemia in granulomatous disorders \[[@SFV058C14]\]. Indeed, in some of the newly reported cases of *Cyp24a1*-inactivating mutations, ketoconazole administration effectively lowered serum 1,25D and calcium levels. However, there is concern about the potential renal and hepatic toxicity of the high doses of ketoconazole required and also in a prolonged duration of treatment with ketoconazole for persistent hypercalcaemia. An important contribution of this case report is that it presents fluconazole as a potentially safer alternative to ketoconazole to attenuate 1,25D synthesis and effectively correct hypercalcaemia in this rare disorder.

Another important consideration to improve therapy is that the incidence of hypercalcaemic episodes in patients with CYP24A1 mutations also associated with periods of higher exposure to sunlight \[[@SFV058C8]\]. This could be explained in part by the described synergy between 25D and 1,25D for VDR activation, as sunlight exposure will increase circulating vitamin D levels that will be converted to 25D by the loosely regulated CYP27A1 and CYP2R1 enzymes. In this case report, the patient was instructed to avoid tanning beds.

Theoretically, inhibition of vitamin D conversion to 25D should help attenuate the hypercalcaemic episodes following sunlight exposure or vitamin D supplementation. One well-recognized inhibitor of vitamin D conversion to 25D is the antiepileptic drug phentobarbital \[[@SFV058C15]\] suggesting its potential as a co-adjuvant to ketoconazole, or the safer fluconazole, to expand the therapeutic strategy to target simultaneously vitamin D conversion to 25D and 25D conversion to 1,25D.
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